Call Text Chat Email Refer a Patient Join a Study

Search

MotherToBaby

Medications and More during pregnancy and breastfeeding

Abatacept (Orencia®)

Selected References

  • Balevic SJ, et al. 2024. Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19: A Secondary Analysis of the ACTIV-1 IM Randomized Clinical Trial. JAMA Netw Open. 7(4):e247615.  
  • Bhimraj A, et al. 2025. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. Clin Infect Dis. 81(Supplement_3):i1-i5.  
  • Chin A, et al. 2025. Recommendations for the Use of Disease-Modifying Antirheumatic Drugs in Pregnancy and Reproductive Health for Patients With Rheumatic Disease: A Scoping Review. Arthritis Care Res (Hoboken). 77(10):1273-1281.  
  • Dernoncourt A, et al. 2023. Fetal and neonatal adverse drug reactions associated with biologics taken during pregnancy by women with autoimmune diseases: Insights from an analysis of the World Health Organization pharmacovigilance database (VigiBase®). BioDrugs. 37(1):73-87. 
  • E.R. Squibb and Sons, L.L.C. (Last updated: October 30, 2023). Orencia drug label. Source: National Library of Medicine. Available at https://dailymed.nlm.nih.gov/dailymed/druginfo.cfm?setid=0836c6ac-ee37-5640-2fed-a3185a0b16eb. Accessed 31 July 2026. 
  • Ghalandari N, et al. 2022. Reported congenital malformations after exposure to non-tumour necrosis factor inhibitor biologics: A retrospective comparative study in EudraVigilance. Br J Clin Pharmacol. 88(12):5378-5388.  
  • Kumar M, et al. 2015. Pregnancy outcomes following exposure to abatacept during pregnancy. Semin Arthritis Rheum. 45(3):351-356. 
  • Makol A, et al. 2011. Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. Drugs. 71(15):1973-1987. 
  • Nadig N, et al. 2025. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept. Clin Infect Dis. 81(Supplement_3):i17-i21.  
  • Ojeda-Uribe M, et al. 2013. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol. 32(5):695-700. 
  • Ostensen M, Förger F. 2011. Treatment with biologics of pregnant patients with rheumatic diseases. Curr Opin Rheumatol. 23(3):293-298. 
  • Partlett R, Roussou E. 2011. The treatment of rheumatoid arthritis during pregnancy. Rheumatol Int. 31(4):445-449. 
  • Pham T, et al. 2012. Abatacept therapy and safety management. Joint Bone Spine. 79 Suppl 1:3-84.  
  • Saito J, et al. 2019. Abatacept concentrations in maternal serum and breast milk during breastfeeding and an infant safety assessment: a case study. Rheumatology (Oxford). 58(9):1692-1694. 

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $1,200,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.